ILiAD Biotechnologies Secures $115M to Accelerate Advanced Pertussis Vaccine Development
February 17, 2026, 3:47 am
ILiAD Biotechnologies, a clinical-stage biotech firm, raised $115 million in Series B funding. RA Capital Management led the investment. Janus Henderson and BNP Paribas Asset Management Alts also participated. The capital will advance BPZE1, an innovative intranasal pertussis vaccine. This vaccine targets *Bordetella pertussis*, the cause of whooping cough. BPZE1 offers durable, comprehensive immunity. It seeks to prevent infection, disease, and transmission. This funding propels a pivotal human challenge trial, addressing an urgent global health need for improved pertussis prevention.
ILiAD Biotechnologies recently achieved a major financial milestone. The company secured an impressive $115 million in an oversubscribed Series B financing round. This substantial capital infusion underscores significant investor confidence. RA Capital Management spearheaded the investment. They demonstrated strategic focus on innovative infectious disease solutions. Other prominent new investors included Janus Henderson Investors and BNP Paribas Asset Management Alts. Existing investors also reaffirmed their commitment. This signals continued belief in ILiAD's proprietary vaccine platform. The addition of Mario Barro, Ph.D., Head of Infectious Diseases at RA Capital, to ILiAD’s Board of Directors further strengthens governance and strategic oversight. This robust funding round sends a clear signal. It highlights the perceived value and potential of ILiAD’s cutting-edge pertussis research. It validates the critical need for advanced prophylactic measures against whooping cough.
The newly acquired funds will propel ILiAD’s core mission. The Weston, FL-based biotechnology firm is singularly dedicated to preventing and treating diseases caused by *Bordetella pertussis*. This focus directly addresses the ongoing global burden of whooping cough. Funds are allocated strategically. They will expand crucial operations. They will significantly accelerate research and development efforts. A primary objective is advancing the company’s lead vaccine candidate, BPZE1. ILiAD is actively engaged in scientific collaboration. It seeks to overcome inherent limitations of current pertussis vaccines. The company investigates the broad impact of *B. pertussis* in human disease. This funding ensures continued validation of its proprietary vaccines through rigorous human clinical trials. It moves closer to market availability.
BPZE1 stands as ILiAD’s flagship innovation. It represents a next-generation live-attenuated pertussis vaccine. Its distinctive feature is intranasal administration. This needle-free approach simplifies delivery. It enhances accessibility. Crucially, BPZE1 is engineered to induce comprehensive immunity. It generates both systemic and mucosal immune responses. Systemic immunity provides broad protection throughout the body. Mucosal immunity acts locally. It specifically targets the respiratory tract. This is the primary site of *Bordetella pertussis* infection. By activating this dual defense, BPZE1 aims to provide more robust and durable protection. It moves beyond the scope of traditional injectable vaccines. It promises to disrupt the pathogen at its entry point. It prevents colonization and subsequent disease.
The strategic design of BPZE1 targets multiple facets of pertussis. It seeks to prevent *Bordetella pertussis* infection outright. It protects against whooping cough symptoms. It also holds the potential to block transmission effectively. Preventing bacterial colonization in the nasal passages of adults and adolescents is a key objective. This could significantly reduce the spread of pertussis. It offers protection, especially to highly vulnerable infants. BPZE1 has shown considerable promise in its development journey. It has been evaluated across six clinical studies. This includes a pivotal human challenge study. Results from this study have been published in a leading scientific journal. The vaccine’s foundational research took place at the renowned Institut Pasteur de Lille in France. This highlights its strong scientific pedigree.
The persistent global challenge of pertussis cannot be overstated. Whooping cough, caused by the highly contagious *Bordetella pertussis* bacterium, remains a severe public health concern. Globally, an estimated 24 million people contract pertussis annually. The disease claims nearly 160,000 lives in children under five years old each year. Despite extensive global vaccination efforts, with coverage rates around 84%, pertussis epidemics continue to occur. Existing vaccines, while important, have proven insufficient in fully controlling disease outbreaks. They often provide waning immunity. More critically, they fail to prevent bacterial carriage and transmission. This fundamental limitation perpetuates the cycle of infection. It underscores the urgent need for a superior vaccine solution like BPZE1.
ILiAD Biotechnologies is poised for critical advancements. The company plans to initiate a pivotal human challenge trial for BPZE1 in 2026. This trial is a crucial step towards regulatory approval. Initial data from this study is expected in 2027. Success would mark a significant breakthrough. BPZE1 possesses the potential to fundamentally redefine pertussis prevention strategies worldwide. Its comprehensive immune response and transmission-blocking capabilities offer a new paradigm. This intranasal pertussis vaccine could drastically reduce the burden of whooping cough. It promises improved global public health outcomes. The substantial Series B funding accelerates this critical work. It brings the world closer to eradicating this persistent, life-threatening disease.
ILiAD Biotechnologies recently achieved a major financial milestone. The company secured an impressive $115 million in an oversubscribed Series B financing round. This substantial capital infusion underscores significant investor confidence. RA Capital Management spearheaded the investment. They demonstrated strategic focus on innovative infectious disease solutions. Other prominent new investors included Janus Henderson Investors and BNP Paribas Asset Management Alts. Existing investors also reaffirmed their commitment. This signals continued belief in ILiAD's proprietary vaccine platform. The addition of Mario Barro, Ph.D., Head of Infectious Diseases at RA Capital, to ILiAD’s Board of Directors further strengthens governance and strategic oversight. This robust funding round sends a clear signal. It highlights the perceived value and potential of ILiAD’s cutting-edge pertussis research. It validates the critical need for advanced prophylactic measures against whooping cough.
The newly acquired funds will propel ILiAD’s core mission. The Weston, FL-based biotechnology firm is singularly dedicated to preventing and treating diseases caused by *Bordetella pertussis*. This focus directly addresses the ongoing global burden of whooping cough. Funds are allocated strategically. They will expand crucial operations. They will significantly accelerate research and development efforts. A primary objective is advancing the company’s lead vaccine candidate, BPZE1. ILiAD is actively engaged in scientific collaboration. It seeks to overcome inherent limitations of current pertussis vaccines. The company investigates the broad impact of *B. pertussis* in human disease. This funding ensures continued validation of its proprietary vaccines through rigorous human clinical trials. It moves closer to market availability.
BPZE1 stands as ILiAD’s flagship innovation. It represents a next-generation live-attenuated pertussis vaccine. Its distinctive feature is intranasal administration. This needle-free approach simplifies delivery. It enhances accessibility. Crucially, BPZE1 is engineered to induce comprehensive immunity. It generates both systemic and mucosal immune responses. Systemic immunity provides broad protection throughout the body. Mucosal immunity acts locally. It specifically targets the respiratory tract. This is the primary site of *Bordetella pertussis* infection. By activating this dual defense, BPZE1 aims to provide more robust and durable protection. It moves beyond the scope of traditional injectable vaccines. It promises to disrupt the pathogen at its entry point. It prevents colonization and subsequent disease.
The strategic design of BPZE1 targets multiple facets of pertussis. It seeks to prevent *Bordetella pertussis* infection outright. It protects against whooping cough symptoms. It also holds the potential to block transmission effectively. Preventing bacterial colonization in the nasal passages of adults and adolescents is a key objective. This could significantly reduce the spread of pertussis. It offers protection, especially to highly vulnerable infants. BPZE1 has shown considerable promise in its development journey. It has been evaluated across six clinical studies. This includes a pivotal human challenge study. Results from this study have been published in a leading scientific journal. The vaccine’s foundational research took place at the renowned Institut Pasteur de Lille in France. This highlights its strong scientific pedigree.
The persistent global challenge of pertussis cannot be overstated. Whooping cough, caused by the highly contagious *Bordetella pertussis* bacterium, remains a severe public health concern. Globally, an estimated 24 million people contract pertussis annually. The disease claims nearly 160,000 lives in children under five years old each year. Despite extensive global vaccination efforts, with coverage rates around 84%, pertussis epidemics continue to occur. Existing vaccines, while important, have proven insufficient in fully controlling disease outbreaks. They often provide waning immunity. More critically, they fail to prevent bacterial carriage and transmission. This fundamental limitation perpetuates the cycle of infection. It underscores the urgent need for a superior vaccine solution like BPZE1.
ILiAD Biotechnologies is poised for critical advancements. The company plans to initiate a pivotal human challenge trial for BPZE1 in 2026. This trial is a crucial step towards regulatory approval. Initial data from this study is expected in 2027. Success would mark a significant breakthrough. BPZE1 possesses the potential to fundamentally redefine pertussis prevention strategies worldwide. Its comprehensive immune response and transmission-blocking capabilities offer a new paradigm. This intranasal pertussis vaccine could drastically reduce the burden of whooping cough. It promises improved global public health outcomes. The substantial Series B funding accelerates this critical work. It brings the world closer to eradicating this persistent, life-threatening disease.